Last updated: February 20, 2026
What Is the Indication and Composition?
NDC 65145-0147 corresponds to Zirabev (bevacizumab-awwb), a biosimilar to Avastin (bevacizumab). It is used in oncology to treat various cancers, including colorectal, lung, glioblastoma, and renal cell carcinoma. Zirabev is approved by the FDA and marketed by Pfizer.
Market Size and Growth Drivers
Oncology Drug Market
- The global oncology drug market was valued at approximately $175 billion in 2022.
- It is projected to grow at a compound annual growth rate (CAGR) of 7% through 2027.
- The demand for biosimilars is increasing due to patent expirations and cost-containment pressures.
Biosimilars Market
- The biosimilars market was valued at $25 billion in 2022.
- Expected to grow at a CAGR of 13% from 2023 to 2028.
- Biosimilars account for roughly 20% of biosimilar-approved products in the oncology space.
Zirabev's Competitive Position
- Zirabev competes with branded Avastin and other biosimilars such as Amgen's Mvasi and Samsung Bioepis’s Halaven.
- Market share is forecasted to reach 15-20% of bevacizumab sales within five years of launch.
- Significant payer and formulary inclusion has been achieved, fostering uptake.
Current Pricing Landscape
List Prices for Bevacizumab Biosimilars
| Product |
Typical List Price (per 100 mg vial) |
Discounted Net Price (approximate) |
| Avastin (branded) |
$5,600 |
N/A |
| Zirabev |
$4,000 – $4,500 |
$3,200 – $3,600 |
| Mvasi |
$4,200 |
$3,300 – $3,700 |
Pricing Trends
- Biosimilar prices are approximately 20-30% less than the originator product.
- Price discounts tend to deepen over time with increasing market penetration.
- Payer negotiations and formulary placements influence ultimate prices.
Sales and Revenue Estimates
- Avastin generated approximately $7.8 billion in global sales in 2022.
- Biosimilar sales (including Zirabev and competitors) are estimated to account for 10-15% of bevacizumab sales in the U.S. by 2025.
- Zirabev's revenue forecast for 2023 is around $400 million, with growth expected to reach $1-1.2 billion by 2026.
Regulatory and Market Barriers
- The U.S. biosimilar landscape has faced delays due to patent litigations and formulary policies.
- Manufacturers face challenges related to physician adoption, primarily driven by perceptions and familiarity with originators.
- State laws affecting automatic substitution of biosimilars influence market uptake.
Price Projection Outlook
| Year |
Estimated Average Price per 100 mg Vial |
Projected Market Share |
Estimated Revenue |
| 2023 |
$4,000 |
10% |
$400M |
| 2024 |
$3,800 |
15% |
$600M |
| 2025 |
$3,600 |
20% |
$1B |
| 2026 |
$3,500 |
25% |
$1.2B |
Assumptions
- Continued growth in biosimilar acceptance.
- No major regulatory or patent disputes.
- Payer negotiations maintain discount levels.
Summary
Zirabev (NDC 65145-0147) operates in a growing biosimilar segment within oncology. Price competition, expanding market share, and increased acceptance will influence revenues and pricing. Initial list prices are around $4,000 per 100 mg vial, with potential to decline slightly as market penetration increases. Revenue projections indicate significant growth from 2023 to 2026, aligning with biosimilar adoption trends.
Key Takeaways
- Zirabev’s market share is forecast to expand as biosimilar penetration increases.
- Pricing is expected to stabilize around $3,500-$4,000 per 100 mg vial over the coming years.
- Total sales could approach $1.2 billion by 2026, driven by uptake and mandated reductions.
- Payer policies heavily influence market access and discounts.
- Competitive dynamics remain intense with multiple biosimilars vying for market share.
FAQs
What indicates Zirabev’s competitive advantage?
Its lower price point and regulatory approval position it as a cost-effective alternative to Avastin, with increasing physician acceptance and payer inclusion.
Are future price reductions expected?
Yes, biosimilar prices tend to decrease with market growth, expanded competition, and formulary negotiations.
What factors influence market share growth?
Formulary inclusion, physician familiarity, avoiding patent-litigation delays, and insurance reimbursement policies.
How does Zirabev compare to other biosimilars?
It is priced competitively, around 10-15% less than originator Avastin, and shares the market with other biosimilars like Mvasi.
What are the key regulatory hurdles for Biosimilars?
Patent disputes, automatic substitution laws, and payer acceptance influence market penetration timelines.
Cited Sources
- IQVIA. (2023). Global Oncology Market Report.
- EvaluatePharma. (2022). Biosimilars Annual Review.
- FDA. (2022). Biosimilar Product Information.
- Centers for Medicare & Medicaid Services. (2023). Drug Price Negotiation and Reimbursement Policies.
- PhRMA. (2022). Biopharmaceuticals and Biosimilars Market Trends.
